FCP

For over a decade, FCP team supported us firmly as a true partner. During that time, we experienced over 2 years of dreadful ITC 337 patent law suit. Our final victory built the foundation for our global business expansion. At critical moments such as a major M&A, FCP vetoed an unfavorable buyout bid, kept the team focused on its course, eventually allowed BMC to complete its own successful IPO on ChiNext market. After more than 10 years of companionship, FCP has become our most trusted partner.

Dr. Zhi ZHUANG, Chairman, BMC Medical Co., Ltd.

BMC Medical was founded in 2001 in a rented shack in the suburb of Beijing. Through twenty two years of dedication, BMC has become the largest commercial ventilator designer and manufacturer in China. Its products are distributed to over 130 countries. FCP has continuously provided BMC with constructive and critical advice since the partnership establishment in 2011. In Nov 2022, BMC was successfully listed on ChiNext market, becoming the largest IPO of that year in Chinese medical device industry. Looking forward into the future, FCP will continue to support BMC as a trusted partner.

When we were still an early stage startup, every decision would bring us one step closer to survival or failure. FCP team has accumulated over a decade of commercial experience as well as organizational best practices, and their critical yet constructive advice guided us during the most difficult time. We are most grateful when they helped us resolve strategic differences among founding partners, and encouraged us to focus on creating world leading products, which turned out to be the best strategy to stay on top of the global competition. Through a successful cross boarder acquisition, we evolved from a startup to a world leading player in the neurovascular field.

Mr. Bing LIU, Chairman, Wallaby Medical Co., Ltd.

Wallaby Medical, founded in Shanghai during 2015, commits to becoming a leading medical technology company to save most stroke patient's lives in the world. Through the merger with Phenox GmbH, Wallaby has become one of the very few players in the world that equipped with comprehensive product portfolio and capability to serve over 60 countries and territories, including but not limited to China, Europe, North America and Japan. FCP invested in Wallaby in 2018 with follow on rounds and continuously supported the company as its most important strategic shareholder.

It's essential to entrepreneurs that we could find a strategic partner who shares the same long term value at an early stage. FCP team firmly supported our choice to develop carbon fiber composite technology with focus on EV industry in very early stage. They provided their best support during our difficult times, so that HRC could steadily pursue a difficult long term pathway and realize sustainable strategic value.

Mr. Yongtao GU, Chairman, Hengrui Corporation

HRC Group, founded in 2014, focuses on R&D and production of advanced carbon fiber composite for global leading customers in auto, aviation, and locomotive industries. FCP has supported HRC's core business and long term strategy since the first investment in 2018. Today, HRC has become a first tier carbon fiber composite producer in the world, and FCP will continuously contribute to HRC's future success.

Investment Professionals

Zihao An

Mr. An focuses on investment in engineering and advanced manufacturing sectors. Before joining FCP, Mr. An worked at Hainan Airlines and Capital Airlines where he took the leading role in the development of operational software systems and led multiple projects of ground-to-air communication technology application. Mr. An holds a Chinese Civil Aviation Flight Dispatcher License.

Mr. An earned a Bachelor's degree in Air Traffic Management from Civil Aviation University and a Master's degree in Business Administration from Shanghai Jiao Tong University.

Grace Gao

Prior to FCP, Ms. Gao worked at IBM China General Manager Office and Technology Service Department, managing the business development in the healthcare, banking, and manufacturing sectors. Ms. Gao was also a founding member of three technology start-ups, covering businesses in hospital systems, smart industrial parks, and supply chain finance.

Ms. Gao holds a Bachelor's Degree in Economics and Master's Degree in Management from Beijing Institute of Technology, a FMBA from Tsinghua University - CUHK.

Sunny Guo

Ms. Guo has experience in both direct investment and FOF investment management. Prior to FCP, she worked at BCG (Australia), Shenzhen Investment Holdings Co. Ltd., Shenzhen Oriental Fortune Capital, and Shenzhen Angel FOF.
She participated and led investments such as Intellifusion Technologies (688343), Readline ,Cellbri Bio. Ms. Guo had also managed over forty funds under government-guided industrial funds, with a broad industry coverage and extensive network resource.
Ms. Guo graduated from Hunan University with a Bachelor degree in Economics and a Master degree in Finance from the Australian National University.

Jian Jiao

Mr. Jiao has more than 13 years of investment experience in both private and public markets. He was trained as sales representative at Siemens Healthcare, and then worked as a fund investment manager at Guosen Securities Economic Research Institute, Gfund Management and PingAn Trust respectively. Mr. Jiao focuses on investment and research in healthcare and advanced manufacturing sectors. He led the investments in SinoUnited Healthcare, Sandstone Medical, Anke Medical, Youlife, Dreamink Technology and HRC Group.

Mr. Jiao holds a Bachelor degree and a Master degree in Biomedical Engineering from Tsinghua University.

Tony Li

Mr. Li has over 10 years of investment experience in the healthcare and technology sectors. He worked as a healthcare industry analyst at Boodell & Co Capital Management LLC in New York prior to FCP. Mr. Li led the investment in Wallaby Medical, ET Healthcare, Health Biotec, Insilico, HiFiBio, Run-Long Medical, and he serves as an advisor for a number of medtech startups.

Mr. Li holds a BA degree from Beijing University of Aeronautics and Astronautics and an MBA from Cheung Kong Graduate School of Business.

Sophia Tang

Ms. Tang joined FCP in 2021 and focuses on industry research and investment in healthcare sectors. Prior to joining FCP, Ms. Tang worked at Legend Capital, Frost & Sullivan, and Minsheng Securities.

Ms. Tang earned a Bachelor's degree in Applied Biology and Biotechnology from the Hong Kong Polytechnic University and a Master's degree in Business Analytics from Washington University in St. Louis.

Zirui Tian

Mr. Tian has more than 15 years of investment experience, he processes in-depth knowledge and industry connections in the healthcare sectors, where he led successful investment in companies such as SonoScape (300633), BMC Medical (301367), Labtech (688056), Medical Systems (603990), etc. Prior to FCP, he served as a Venture Partner at WI Harper Group, specialized in the healthcare sectors. He was also a serial entrepreneur and founded two hi-tech companies.

Mr. Tian holds a Master Degree in Biomedical Engineering from Tsinghua University, and an MBA from Duke University.

Natalie Wang

Ms. Wang has over 5 years of experience in overseas capital raising and business development. Prior to FCP, she worked at InnoVision Capital in charge of investor relations of USD funds and China Railway Construction Corporation leading the investment and financing businesses in 9 countries of SEA region. She has accumulated extensive resources in capital raising and overseas industry network, exploring cross-border opportunities for domestic companies and establishing strategic parterships with local corporates and families.
Ms. Wang earned double Bachelor degrees in Financial Economics and Applied Mathematics from University of Rochester and a Master degree in Public Policy from University of Chicago.

Roger Wu

Mr. Wu has over 20 years of experience in investment banking and direct investment, his experience includes: Managing Director at CITIC Securities, in charge of investment and operation, member of Investment Committee; Senior VP at Lehman Brothers Asia, responsible for operating direct investment fund (GOG); and Investment manager at Henderson Asia Fund, in charge of investment and fund management.

Mr. Wu holds a Bachelor Degree in Economics and Industrial Control from Columbia University.

Hong Kong

5/F, United Centre, 95 Queensway, Admiralty, Hong Kong

Beijing

E1, 1712, Beijing Oriental Plaza, 1 East ChangAn Avenue, Dongcheng District, Beijing

Shanghai

3807, Park Place, 1601 West Nanjing Road, Jing’an District, Shanghai